Treatment Outcome of Breast Cancer with Pathologically Proven Synchronous Ipsilateral Supraclavicular Lymph Node Metastases.
10.4048/jbc.2015.18.2.167
- Author:
Jinhong JUNG
1
;
Su Ssan KIM
;
Seung Do AHN
;
Sang wook LEE
;
Sei Hyun AHN
;
Byung Ho SON
;
Jong Won LEE
;
Eun Kyung CHOI
Author Information
1. Department of Radiation Oncology, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Breast neoplasms;
Lymph nodes;
Neoplasm metastasis;
Radiotherapy
- MeSH:
Breast Neoplasms*;
Disease-Free Survival;
Drug Therapy;
Humans;
Lymph Node Excision;
Lymph Nodes*;
Multivariate Analysis;
Neoplasm Metastasis*;
Prognosis;
Radiotherapy;
Treatment Outcome*;
Trastuzumab
- From:Journal of Breast Cancer
2015;18(2):167-172
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The aim of this study was to investigate the prognosis, patterns of failure, and prognostic factors for breast cancer patients with pathologically proven synchronous ipsilateral supraclavicular lymph node (ISCLN) metastases. METHODS: We reviewed the records of breast cancer patients with pathologically proven ISCLN metastases. Local aggressive treatment was defined as treatment including surgery, axillary lymph node dissection (ALND), ISCLN excision, radiotherapy (RT), and chemotherapy. RESULTS: A total of 111 patients were included. The 5-year overall survival (OS) and disease-free survival (DFS) rates were 64.2% and 56.2%, respectively. On univariate analysis, RT, ALND, trastuzumab treatment, hormone receptor (HR) status, and local aggressive treatment were identified as significant factors for OS. The 5-year OS for 73 patients who received local aggressive treatment was superior to that of 38 patients who received nonaggressive treatment (70.9% vs. 49.3%, p=0.036). Multivariate analysis showed that RT, HR status, and trastuzumab were significant variables for the 5-year OS and DFS. CONCLUSION: Multimodality treatment with surgery, taxane-based chemotherapy, hormone therapy, and RT is strongly recommended for breast cancer patients with synchronous ISCLN metastases.
